Reata Pharmaceuticals, Inc.
Simbols: RETA
NASDAQ
172.36
USDTirgus cena šodien
-89.3629
P/E koeficients
0.0000
PEG koeficients
6.57B
MRK Cap
- 0.00%
DIV ienesīgums
Reata Pharmaceuticals, Inc. (RETA) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1474.56 | 387.5 | 590.3 | 818.1 | ||||||||||
balance-sheet.row.short-term-investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 16.95 | 0 | 0 | 22.2 | ||||||||||
balance-sheet.row.inventory | 8.65 | 0 | 0 | -22.2 | ||||||||||
balance-sheet.row.other-current-assets | 77.1 | 10.3 | 6.2 | 29.2 | ||||||||||
balance-sheet.row.total-current-assets | 1577.27 | 397.8 | 596.5 | 847.3 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 459.6 | 116.4 | 138.4 | 4.9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 17.44 | 0.3 | 0.2 | 5.3 | ||||||||||
balance-sheet.row.total-non-current-assets | 477.04 | 116.7 | 138.5 | 10.3 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 2054.3 | 514.5 | 735 | 857.6 | ||||||||||
balance-sheet.row.account-payables | 60.53 | 18.7 | 13.5 | 4.8 | ||||||||||
balance-sheet.row.short-term-debt | 13.07 | 2.2 | 3.1 | 87.5 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 534.25 | 117.3 | 136 | 0 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 4.7 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 131.23 | 38.1 | 35.7 | 22.3 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 1869.5 | 521.2 | 495 | 321 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 470.98 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.total-liab | 2158.86 | 580.2 | 549 | 440.2 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -6223.86 | -1567.5 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 4566.18 | 1501.8 | 0 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 501.33 | 514.5 | -706.6 | -518.1 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 501.33 | - | - | - | ||||||||||
Total Investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.total-debt | 544.11 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.net-debt | 336.1 | 77.2 | -454.2 | -818.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -87.62 | -311.9 | -297.4 | -247.8 | ||||||||||
cash-flows.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
cash-flows.row.deferred-income-tax | -291.96 | 0 | 0 | 11.2 | ||||||||||
cash-flows.row.stock-based-compensation | 87.84 | 58.7 | 56.8 | 57.6 | ||||||||||
cash-flows.row.change-in-working-capital | 7.84 | 9.3 | -49.6 | -172.7 | ||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.inventory | -13.28 | 0 | 0 | 0 | ||||||||||
cash-flows.row.account-payables | 11.97 | 5.2 | 8.7 | 2.9 | ||||||||||
cash-flows.row.other-working-capital | 9.16 | 4.1 | -58.3 | -175.6 | ||||||||||
cash-flows.row.other-non-cash-items | 34.44 | 38.5 | 53.3 | 28.1 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -248.34 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.acquisitions-net | 75 | 0 | 0 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -631.88 | -661.9 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 617.42 | 320 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 59.42 | -345.2 | -1.3 | -0.9 | ||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -167.2 | ||||||||||
cash-flows.row.common-stock-issued | 222.73 | 0 | 333.3 | 333.3 | ||||||||||
cash-flows.row.common-stock-repurchased | 22.65 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -231.54 | 1.5 | -324.1 | 311 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 90.61 | 1.5 | 9.1 | 477.1 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 167.98 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -98.31 | -547.9 | -227.9 | 153.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 208.01 | 42.3 | 590.3 | 818.1 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 306.32 | 590.3 | 818.1 | 664.3 | ||||||||||
cash-flows.row.operating-cash-flow | -248.34 | -204.3 | -235.7 | -322.3 | ||||||||||
cash-flows.row.capital-expenditure | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.free-cash-flow | -249.46 | -207.5 | -237 | -323.3 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 24.39 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.cost-of-revenue | 0.85 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit | 23.55 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 203.31 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 114.18 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.operating-expenses | 364.3 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.cost-and-expenses | 365.15 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.interest-income | 0 | 6 | 0.2 | 0 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.total-operating-expenses | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.ebitda-caps | -332.65 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -59.48 | -270.2 | -244.7 | -226.3 | ||||||||||
income-statement-row.row.income-before-tax | -87.68 | -311.9 | -297.8 | -270.2 | ||||||||||
income-statement-row.row.income-tax-expense | 0.25 | 0 | -0.5 | -22.5 | ||||||||||
income-statement-row.row.net-income | -80.06 | -311.9 | -297.4 | -247.8 |
Biežāk uzdotie jautājumi
Kas ir Reata Pharmaceuticals, Inc. (RETA) kopējie aktīvi?
Reata Pharmaceuticals, Inc. (RETA) kopējie aktīvi ir 514491000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 22941000.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.965.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -6.010.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -3.282.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -2.438.
Kāda ir Reata Pharmaceuticals, Inc. (RETA) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -311901000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 119464000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 280250000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 48843000.000.